Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Next-generation sequencing for measuring minimal residual disease in AML.

Nature reviews. Clinical oncology - 1 Aug 2018

Walter Roland B, Appelbaum Frederick R

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to High-Throughput Nucleotide Sequencing
Share to Leukemia, Myeloid, Acute
Share to Mutation
Share to Neoplasm, Residual

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29795270
DOI: 10.1038/s41571-018-0040-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Next-generation sequencing for measuring minimal residual disease in AML.PMID 29795270Read ↗

Next‐generation sequencing for measurable residual disease detection in acute myeloid leukaemiaSemantic proximity Read ↗

Minimal Residual Disease Monitoring with Next-Generation Sequencing Methodologies in Hematological MalignanciesSemantic proximity Read ↗

Sequencing-Based Measurable Residual Disease Testing in Acute Myeloid LeukemiaSemantic proximity Read ↗

Accurate and Sensitive Analysis of Minimal Residual Disease in Acute Myeloid Leukemia Using Deep Sequencing of Single Nucleotide VariationsSemantic proximity Read ↗

Next-generation sequencing in the diagnosis and minimal residual disease assessment of acute myeloid leukemiaSemantic proximity Read ↗

Monitoring minimal residual disease in AML.Semantic proximity Read ↗

A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutationsSemantic proximity Read ↗

Patient-tailored analysis of minimal residual disease in acute myeloid leukemia using next-generation sequencing.Semantic proximity Read ↗

Novel Tools for Diagnosis and Monitoring of AML.Semantic proximity Read ↗

A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia.Semantic proximity Read ↗

Minimal residual disease in multiple myeloma: defining the role of next generation sequencing and flow cytometry in routine diagnostic useSemantic proximity Read ↗

Molecular Minimal Residual Disease Testing in Acute Myeloid Leukemia: A Review for the Practicing Clinician.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.